

Anti-HLA-Drb1 Monoclonal Antibody

Catalog # ABO14757

Product Information

Application	WB, IHC, IF, ICC
Primary Accession	P01911
Host	Rabbit
Isotype	Rabbit IgG
Reactivity	Human
Clonality	Monoclonal
Format	Liquid
Description	Anti-HLA-Drb1 Monoclonal Antibody . Tested in WB, IHC, ICC/IF applications. This antibody reacts with Human.

Additional Information

Gene ID	3123
Other Names	HLA class II histocompatibility antigen, DRB1 beta chain, Human leukocyte antigen DRB1, HLA-DRB1, HLA-DRB1 (HGNC:4948)
Calculated MW	29966
Application Details	WB 1:500-1:2000 IHC 1:50-1:200 ICC/IF 1:50-1:200
Source	Eukaryota
Contents	Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA.
Clone Names Immunogen	Clone: AFGA-8 A synthesized peptide derived from human HLA-Drb1 Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells.
Purification	Affinity-chromatography
Storage	Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles.

Protein Information

Name	HLA-DRB1 (HGNC:4948)
Function	A beta chain of antigen-presenting major histocompatibility complex class II

(MHCII) molecule. In complex with the alpha chain HLA- DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:[15265931](#), PubMed:[16148104](#), PubMed:[22327072](#), PubMed:[27591323](#), PubMed:[29884618](#), PubMed:[31495665](#), PubMed:[8642306](#)). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:[8145819](#)). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor- resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:[31495665](#)). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:[17182262](#), PubMed:[23783831](#)). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides (PubMed:[25413013](#)). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:[8145819](#)).


Cellular Location

Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Autolysosome membrane Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation (PubMed:18305173). Component of immunological synapses at the interface between T cell and APC (PubMed:29884618).

Tissue Location

Expressed in professional APCs: monocyte/macrophages, dendritic cells and B cells (at protein level) (PubMed:19830726, PubMed:23783831, PubMed:31495665). Expressed in thymic epithelial cells (at protein level) (PubMed:23783831)

Images



Western blot analysis of HLA-Drb1 expression in Ramos cell lysate.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.